TherapeuticsMD Reports First Quarter 2013 Financial Results Business Wire BOCA RATON, Fla. -- May 8, 2013 TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women’s healthcare company focused on developing and commercializing products targeted exclusively for women, today announced financial results for the three months ended March 31, 2013. First Quarter and Subsequent Highlights: *Net revenue for the quarter ended March 31, 2013 was $1.5 million compared with approximately $722,000 in the first quarter of 2012; *Net loss improved to $6.4 million for the quarter ended March 31, 2013 compared with a net loss of $13.3 million in the first quarter of 2012; *Cash and cash equivalents were $38.8 million at March 31, 2013, compared with $1.6 million at December 31, 2012; *The Company generated approximately $48.5 million in net proceeds through the issuance and sale of approximately 31.4 million shares of TXMD common stock in an underwritten public offering, which includes net proceeds of approximately $3.1 million from the issuance and sale of approximately 2.0 million shares to cover over-allotments; and *TXMD common stock commenced trading on the NYSE MKT on April 23, 2013. “With our newly strengthened balance sheet, NYSE MKT listing, and strong portfolio of bioidentical hormone therapy product candidates, we believe TherapeuticsMD is well positioned for success as we execute our strategy to become a leader in the women’s healthcare field,” said Robert G. Finizio, Chief Executive Officer. “We look forward to initiating pivotal Phase III clinical trials with two of our bioidentical hormone therapy product candidates, 17β estradiol/ progesterone combination and lower dose oral progesterone, which we believe can achieve equivalent efficacy at lower doses of active compound and lower cost to patients versus currently available products. We expect to file an IND application for an additional hormone therapy candidate, a novel estradiol suppository, later this year.” First Quarter Results Net revenue for the first quarter of 2013 totaled $1.5 million, compared with net revenue of approximately $722,000 for the year ago quarter. The increase of approximately $815,000, or 113%, was directly attributable to an increase in sales territories, sales people and new prescription products. Cost of goods sold increased by approximately $44,000, or 13%, for the three months ended March 31, 2013 compared with the prior year quarter. Research and development expenses increased to $1.6 million during the first quarter of 2013 compared with approximately $400,000 in the first quarter of 2012, due to costs incurred for the development of our new hormone replacement therapy and prescription prenatal products. Selling, general and administrative expenses increased to $4.5 million during the first quarter of 2013 compared with $2.8 million in the first quarter of 2012. As a result, our operating loss was $4.9 million in the first quarter of 2013 compared with $2.9 million in the first quarter of 2012. Other non-operating expenses decreased by approximately $9.0 million for the first quarter of 2013 compared with the comparable quarter in 2012. This decrease resulted primarily from a loss on extinguishment of debt incurred during 2012, partially offset by an increase in amortization of debt discount of approximately $1.0 million and amortization of financing costs of approximately $300,000. As a result, net loss for the first quarter of 2013 was $6.4 million, or $0.06 per basic and diluted share, compared with a net loss of $13.3 million, or $0.16 per basic and diluted share, in the first quarter of 2012. Cash and cash equivalents increased to $38.8 million at March 31, 2013. About Hormone Therapy Hormone therapy (HT) is the administration of hormones to supplement a lack of naturally occurring hormones. HT options include natural, bioidentical, and non-bioidentical (conjugated) hormones. HT is projected to be the largest growth segment in the overall women’s health market. The potential market for pharmacy-compounded, bioidentical hormone therapy products is estimated to be approximately $1.5 billion per year. About TherapeuticsMD, INC. TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. We manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins and cosmetics, under our vitaMedMD^® and BocaGreenMD™ brands. We are currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. We are also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com, and www.bocagreenmd.com. vitaMedMD^® is a registered trademark and TherapeuticsMD™ and BocaGreenMD™ are trademarks of TherapeuticsMD, Inc. Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company’s belief that it is well positioned for success as it executes its strategy to become a leader in the women’s healthcare field, the Company’s expectations with respect to the timing of the Company’s planned clinical trials, the Company’s belief that it can achieve equivalent efficacy at lower doses of active compound and lower cost to patients versus currently available products, and the Company’s expectations with respect to the timing of filing an IND application, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to: timely and successful completion of clinical studies and the results thereof; challenges and costs inherent in product marketing; the risks and uncertainties associated with economic and market conditions; risks and uncertainties associated with TherapeuticsMD’s business and finances in general; and other risks detailed in TherapeuticsMD’s filings with the U.S. Securities and Exchange Commission including its annual report on Form 10-K filed on March 12, 2013, reports on Form 10-Q and Form 8-K, and other such filings. These forward-looking statements are based on current information that may change. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and TherapeuticsMD undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. THERAPEUTICSMD, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2013 December 31, 2012 (Unaudited) ASSETS Current Assets: Cash $ 38,779,563 $ 1,553,474 Accounts receivable, net of allowance for doubtful accounts of $63,843 and $42,048, respectively 602,824 606,641 Inventory 1,337,870 1,615,210 Other current assets 2,175,520 751,938 Total current assets 42,895,777 4,527,263 Fixed assets, net 83,875 65,673 Other Assets: Prepaid consulting expense 863,523 953,655 Intangible assets 317,250 239,555 Security deposit 31,949 31,949 Total other assets 1,212,722 1,225,159 Total assets $ 44,192,374 $ 5,818,095 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities: Accounts payable $ 1,840,811 $ 1,641,366 Deferred revenue 1,142,373 1,144,752 Other current liabilities 1,144,918 725,870 Line of credit 100,000 - Accrued interest 21,595 - Total current liabilities 4,249,697 3,511,988 Long-Term Liabilities: Notes payable, net of debt discount of - 3,589,167 $0 and $1,102,680, respectively Accrued interest - 150,068 Total long-term liabilities - 3,739,235 Total liabilities 4,249,697 7,251,223 Commitments and Contingencies Stockholders' Equity (Deficit): Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding - - Common stock - par value $0.001; 250,000,000 shares authorized; 129,196,747 and 99,784,982 issued and 129,196 99,785 outstanding, respectively Additional paid-in capital 98,302,447 50,580,400 Accumulated deficit (58,488,966 ) (52,113,313 ) Total stockholders' equity (deficit) 39,942,677 (1,433,128 ) Total liabilities and stockholders' $ 44,192,374 $ 5,818,095 equity (deficit) THERAPEUTICSMD, INC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2013 2012 (Unaudited) (Unaudited) Revenues, net $ 1,537,195 $ 721,692 Cost of goods sold 380,346 336,124 Gross profit 1,156,849 385,568 Operating expenses: Sales, general, and administration 4,526,582 2,827,050 Research and development 1,565,201 411,961 Depreciation and amortization 7,957 14,578 Total operating expense 6,099,740 3,253,589 Operating loss (4,942,891 ) (2,868,021 ) Other income (expense) Interest expense (1,165,831 ) (101,973 ) Financing costs (263,987 ) - Loan guaranty costs (2,944 ) (11,745 ) Loss on extinguishment of debt - (10,307,864 ) Total other income (expense) (1,432,762 ) (10,421,582 ) Loss before taxes (6,375,653 ) (13,289,603 ) Provision for income taxes - - Net loss $ (6,375,653 ) $ (13,289,603 ) Loss per share, basic and diluted: Net loss per share, basic and diluted $ (0.06 ) $ (0.16 ) Weighted average number of common shares outstanding 103,052,956 84,556,216 THERAPEUTICSMD, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Three Months Ended March 31, 2013 2012 (Unaudited) (Unaudited) CASH FLOWS FROM OPERATING ACTIVITES Net loss $ (6,375,653 ) $ (13,289,603 ) Adjustments to reconcile net loss to net cash flows used in operating activities: Depreciation 4,703 7,008 Amortization of intangible assets 3,254 7,570 Provision for doubtful accounts 21,795 - Amortization of debt discount 1,102,680 53,292 Stock based compensation 609,030 88,585 Amortization of deferred financing costs 263,987 - Stock based expense for services 112,306 55,371 Loan guaranty costs 2,944 11,745 Loss on debt extinguishment - 10,307,864 Changes in operating assets and liabilities: Accounts receivable (17,978 ) (85,332 ) Inventory 277,340 45,410 Other current assets (731 ) 51,970 Accounts payable 199,445 301,246 Accrued interest (128,473 ) 45,749 Accrued expenses and other current 419,048 (52,860 ) liabilities Deferred revenue (2,379 ) - Net cash flows used in operating (3,508,682 ) (2,451,985 ) activities CASH FLOWS FROM INVESTING ACTIVITIES Patent costs, net of abandoned costs (80,949 ) (12,101 ) Purchase of property and equipment (22,905 ) (32,386 ) Net cash flows used in investing (103,854 ) (44,487 ) activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from revolving credit note 400,000 - Repayment of revolving credit note (400,000 ) - Proceeds from sale of common stock, net 45,430,472 - Proceeds from notes and loans payable 100,000 2,400,000 Repayment of notes payable (4,691,847 ) (779 ) Proceeds from exercise of warrants - 165,999 Net cash flows provided by financing 40,838,625 2,565,220 activities Increase in cash 37,226,089 68,748 Cash, beginning of period 1,553,474 126,421 Cash, end of period $ 38,779,563 $ 195,169 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for interest $ 191,258 $ 2,112 Cash paid for income taxes $ - $ - SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES: Warrants issued for financing $ 1,711,956 $ - Contact: TherapeuticsMD, Inc. Dan Cartwright, 561-961-1930 Chief Financial Officer Dan.Cartwright@TherapeuticsMD.com or Investor Relations: Lisa M. Wilson, 917-543-9932 In-Site Communications email@example.com
TherapeuticsMD Reports First Quarter 2013 Financial Results
Press spacebar to pause and continue. Press esc to stop.